SCHEMBL4162323

SCHEMBL4162323

O=C(Cc1ccc(O)cc1)NC(Cc1ccccc1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MME P08473 3/20 0.63
CHRNA1 P02708 3/20 0.62
CHRNG P07510 3/20 0.62
CHRNB1 P11230 3/20 0.62
CHRND Q07001 3/20 0.62
ITGB3 P05106 1/20 0.62
ITGA2B P08514 1/20 0.62
GRIA1 P42261 1/20 0.59
ACE P12821 6/20 0.59
CTSL P07711 1/20 0.57
CTSB P07858 1/20 0.57
CTSS P25774 1/20 0.57
FOLH1 Q04609 1/20 0.56
NAALAD2 Q9Y3Q0 1/20 0.56
GPR34 Q9UPC5 1/20 0.55
CPA1 P15085 1/20 0.54
ACE2 Q9BYF1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4162326 1.00 MME (0.63) MMECHRNA1CHRNGCHRNB1CHRND
SCHEMBL4160727 1.00 MME (0.63) MMECHRNA1CHRNGCHRNB1CHRND
SCHEMBL4160723 1.00 MME (0.63) MMECHRNA1CHRNGCHRNB1CHRND
SCHEMBL27840664 1.00 MME (0.63) MMECHRNA1CHRNGCHRNB1CHRND
SCHEMBL4161387 0.95 ACE (0.62) MMECHRNA1CHRNGCHRNB1CHRND
SCHEMBL4161392 0.95 ACE (0.62) MMECHRNA1CHRNGCHRNB1CHRND
SCHEMBL28522339 0.93 CHRNA1 (0.60) MMECHRNA1CHRNGCHRNB1CHRND
SCHEMBL10504767 0.92 ITGB3 (0.65) MMEITGB3ITGA2BACECTSL
SCHEMBL4144665 0.92 ITGB3 (0.65) MMEITGB3ITGA2BACECTSL
SCHEMBL4144668 0.92 ITGB3 (0.65) MMEITGB3ITGA2BACECTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112384495-B Novel modulators of metabotropic and ion-channel transmembrane receptors and uses thereof IBD治疗学有限责任公司 2023-07-18 CN claimed
EP-1876169-B1 PHENYL-CONTAINING N-ACYL AMINE AND AMINOACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF OBSCHESTVO S OGRANICHENNOI OTVETSTENNOSTIYU PHARMENTPR (RU) 2015-12-30 EP claimed
CN-101180267-B Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof OBSCHESTVO S OGRANICHENNOI OTV 2015-06-17 CN claimed
US-8309766-B2 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof Obschestvo S. Organichennoi Otvetstvennostiyu Pharmenterprises (RU) 2012-11-13 US claimed
US-20090111874-A1 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) 2009-04-30 US claimed
EP-1876169-A1 PHENYL-CONTAINING N-ACYL AMINE AND AMINOACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) 2008-01-09 EP claimed
CN-110167547-B Multi-target drugs for treating diseases in mammals 欧亚制药有限责任公司 2024-04-05 CN disclosed
CN-112384495-B Novel modulators of metabotropic and ion-channel transmembrane receptors and uses thereof IBD治疗学有限责任公司 2023-07-18 CN disclosed
US-11584709-B2 Multitarget drug for treating diseases in mammals “PHARMENTERPRISES EURASIA” LIMITED LIABILITY COMPANY (RU) 2023-02-21 US disclosed
US-11584709-B2 Multitarget drug for treating diseases in mammals “PHARMENTERPRISES EURASIA” LIMITED LIABILITY COMPANY (RU) 2023-02-21 US disclosed
US-20210284600-A1 NOVEL MULTITARGET DRUG FOR TREATING DISEASES IN MAMMALS "PHARMENTERPRISES EURASIA" LIMETED LIABILITY COMPANY (RU) 2021-09-16 US disclosed
US-20210284600-A1 NOVEL MULTITARGET DRUG FOR TREATING DISEASES IN MAMMALS "PHARMENTERPRISES EURASIA" LIMETED LIABILITY COMPANY (RU) 2021-09-16 US disclosed
CN-112384495-A Novel modulators of metabolic and ion channel transmembrane receptors and uses thereof IBD治疗学有限责任公司 2021-02-19 CN disclosed
US-20130109880-A1 PHENYL-N-ACYL DERIVATIVES OF AMINES AND AMINO ACIDS, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION AND USE THEREOF OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) 2013-05-02 US disclosed
US-8309766-B2 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof Obschestvo S. Organichennoi Otvetstvennostiyu Pharmenterprises (RU) 2012-11-13 US disclosed
US-8309766-B2 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof Obschestvo S. Organichennoi Otvetstvennostiyu Pharmenterprises (RU) 2012-11-13 US disclosed
US-8309766-B2 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof Obschestvo S. Organichennoi Otvetstvennostiyu Pharmenterprises (RU) 2012-11-13 US disclosed
US-20090111874-A1 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) 2009-04-30 US disclosed
US-20090111874-A1 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) 2009-04-30 US disclosed
US-20090111874-A1 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284600-A1 NOVEL MULTITARGET DRUG FOR TREATING DISEASES IN MAMMALS CTSB, CCKBR, BDKRB1 MME 491/4885CHRNA1 1113/4885CHRNG 1099/4885
US-20130109880-A1 PHENYL-N-ACYL DERIVATIVES OF AMINES AND AMINO ACIDS, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION AND USE THEREOF MAOA, PAH, MAOB MME 613/4885CHRNA1 384/4885CHRNG 501/4885
US-20090111874-A1 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof PAH, MAOA, APEH MME 634/4885CHRNA1 530/4885CHRNG 761/4885
US-11584709-B2 Multitarget drug for treating diseases in mammals CTSB, CCKBR, BDKRB1 MME 573/4885CHRNA1 1244/4885CHRNG 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.